AMCX vs META

AMCX's Piotroski F-Score of 4/9 indicates weak financial health, signaling distress in operational efficiency and capital structure. The absence of an Altman Z-Score raises red flags for potential bankruptcy risk, especially given a high Debt/Equity ratio of 1.83. While the stock trades at a deeply discounted valuation (P/E 4.34, Price/Book 0.31), its negative revenue growth (-0.80% YoY) and inconsistent earnings performance undermine long-term viability. The Graham Number of $29.31 suggests significant undervaluation, but the intrinsic value of $11.62 reflects low growth expectations and high risk. Overall, the combination of weak fundamentals, poor insider sentiment, and deteriorating trends makes the stock a high-risk proposition.

META exhibits exceptional fundamental health with a Piotroski F-Score of 8/9, indicating strong financial strength across profitability, leverage, and operating efficiency. While the current price of $612.42 trades at a premium to the Graham Number ($213.17) and the growth-based Intrinsic Value ($542.14), the PEG ratio of 0.94 suggests the stock is undervalued relative to its high growth rate. Strong revenue growth (23.8%) and a low forward P/E (17.03) outweigh the bearish technical trend and insider selling. The company's dominant market position and consistent earnings beats support a bullish long-term outlook.